Hepatoprotective potential of isoquercitrin against type 2 diabetes-induced hepatic injury in rats

Citations Over TimeTop 10% of 2017 papers

Abstract

Non-alcoholic fatty liver disease is a main complication of type 2 diabetes. Isoquercitrin are employed for antidiabetic therapies, but the effects on liver function and the hepatocytes are unclear. The aim of this study was to investigate the effects of isoquercitrin on the T2DM-induced hepatic injury in rats. Isoquercitrin (10 mg/kg/d, 30 mg/kg/d), sitagliptin phosphate (10 mg/kg/d) was given orally for 21 days. The administration of isoquercitrin at 10 mg/kg/d and 30 mg/kg/d showed a dose dependent. Compare to the negative control (treated with saline), rats medicated with isoquercitrin (30 mg/kg/d) and sitagliptin phosphate (10 mg/kg/d) improved the clinical symptoms, FBG and glucose tolerance, reduced serum ALT, AST and IR, but increased TP, Alb, SOD, GSH, MDA, HDL-C, INS and GLP-1. On histology, Rats of these to groups presented nearly normal liver tissue and Langerhans, degeneration, necrosis and apoptosis were markedly reduced. Instead, hepatocytes showed regenerate. These two groups also showed significant increase in mRNA expression of PKA, AKT, PKCa, InsR and PI3K, and a decrease in DPP-IV mRNA level. These results indicated that treatment with isoquercitrin protects against hepatic injury by T2DM.

Related Papers

• → De novo Malignancy and Recurrent Alcoholic Cirrhosis Account for 70% of Deaths in Patients Transplanted for End-Stage Alcoholic Liver Disease(2016)6 cited
• → S2064 Diagnosis of Cirrhosis in Alcoholic Liver Disease (ALD): Is There a Place for Transient Elastography?(2008)2 cited
• Investigation and analysis on the status of diabetes cognition among COPD patients complicated with diabetes mellitus(2014)
• NAFLD or MAFLD(2021)
• → Whole blood acetaldehyde concentrations in alcoholic cirrhosis and non alcoholic liver disease(1985)